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ABSTRACT
Objective: To conduct a literature review on the diagnosis and management of Paget’s disease 
of bone. Materials and methods: This scientific statement was generated by a request from the 
Brazilian Medical Association (AMB) to the Brazilian Society of Endocrinology and Metabolism 
(SBEM) as part of its Clinical Practice Guidelines program. Articles were identified by searching 
in PubMed and Cochrane databases as well as abstracts presented at the Endocrine Socie-
ty, Brazilian Society for Endocrinology Annual Meetings and the American Society for Bone 
and Mineral Research Annual Meeting during the last 5 years. Grading quality of evidence and 
strength of recommendation were adapted from the first report of the Oxford Centre for Evi-
dence-based Medicine. All grades of recommendation, including “D”, are based on scientific evi-
dence. The differences between A, B, C and D, are due exclusively to the methods employed in 
generating evidence. Conclusion: We present a scientific statement on Paget’s disease of bone 
providing the level of evidence and the degree of recommendation regarding causes, clinical 
presentation as well as surgical and medical treatment. Arq Bras Endocrinol Metab. 2014;58(6):587-99
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RESUMO
Objetivo: Conduzir uma atualização das últimas evidências científicas a respeito da apresen-
tação, diagnóstico e manejo clínico da doença de Paget óssea. Materiais e métodos: Este do-
cumento foi concebido pelo Departamento de Metabolismo Ósseo da Sociedade Brasileira de 
Endocrinologia e Metabologia (SBEM) a partir daquele oriundo do Programa de Diretrizes da 
Associação Médica Brasileira (AMB). Realizamos uma revisão dos artigos mais relevantes obti-
dos nos bancos de dados PubMed e Cochrane, além de abstracts apresentados nos encontros 
anuais da Endocrine Society, Sociedade Brasileira de Endocrinologia e da American Society 
for Bone and Mineral Research dos últimos cinco anos e classificamos as evidências em níveis 
de recomendações de acordo com a força científica por tipo de estudo, adaptando o primei-
ro relato do “Oxford Centre for Evidence-based Medicine”. Todos os graus de recomendação, 
incluindo-se o “D”, foram baseados em evidência científica, sendo as diferenças entre o A, B, 
C e D devidas exclusivamente ao desenho empregado na geração da evidência. Conclusão: 
Apresentamos uma atualização científica a respeito da doença de Paget óssea, classificando 
e graduando em níveis de recomendações as principais evidências científicas sobre as suas 
causas, as variadas formas de apresentação, seu diagnóstico e tratamento. Arq Bras Endocrinol Metab. 
2014;58(6):587-99
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INTRODUCTION
Paget’s disease of bone is a metabolic bone disease characterized by very high rates of bone remodeling 
which lead to bone expansion, trabecular disorganization 
with a consequent decreases in strength and quality (1). 
It has avariable geographic distribution worldwide, 
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being most commonly encountered in white Euro­
peans, and those of European descent over 55 years of 
age (2,3). In Brazil, a prevalence study in a city originally 
colonized by Europeans identified rates comparable to 
those encountered in southern Europe (3). The etiology 
of the disease remains controversial, but genetic factors 
are involved as well as environmental factors (1,4). The 
diagnosis is made primarily by characteristic radiological 
findings and the most common complications are pa­
thologic fractures, bone deformities and osteoarthrosis. 
MATERIALS AND METHODS
This scientific statement was generated by a request from 
the Brazilian Medical Association (AMB) to the Brazilian 
Society for Endocrinology as part of its Clinical Practice 
Guidelines program. Through the Brazilian Society for 
Endocrinology’s Department of Bone Metabolism, a task 
force was established. A draft of this report was submitted 
for comment to the membership of the Brazilian Medical 
Association and Brazilian Society of Endocrinology. This 
report represents the completion of this process.
Grading quality of evidence and strength of recom­
mendation were adapted from the first report of the 
Oxford Centre for Evidence­Based Medicine, detailed 
described elsewhere (5) and summarized in table 1. 
Grades of recommendation are reported, as follows: 
A: More consistent experimental or observational 
trials.
B: Less consistent experimental or observational 
trials.
C: Case reports (non­controlled trials).
D: Opinion without critical evaluation, based on 
consensus, physiological studies or animal mo­
dels.
Articles were identified by searching in PubMed and 
Cochrane databases, as well as abstracts presented at 
the Endocrine Society, American Society for Bone and 
Brazilian Society for Endocrinology Annual Meetings 
during the last 5 years. References are listed numeri­
cally in order of appearance in the text, followed by the 
levels of evidence. 
EPIDEMIOLOGY
The highest prevalence of Paget’s disease of bone is 
found in England, the United States, Australia and 
New Zealand, mainly among patients older than 55 
years (4). In other locations, such as Asia, it is a rare 
disorder (6,7) (C4), as it is in Scandinavia (4) and most 
of Latin America (8) (C4).
PDB has been linked to white ancestry in European 
and other countries, being less common in people who 
are not of European origin. A study published in 2006 
on reported cases of Paget’s disease in Latin America 
over the past 30 years showed that a total of 1,149 
cases of Paget’s disease had been previously published 
in Latin America, more than half of them in Argentina 
and Brazil (9) (C4).
One report from Italy showed a 0.74% radiographic 
prevalence (n = 8 of 1,068 patients evaluated) of pelvic 
PDB in rural regions of Calabria, located in the sou­
thern part of the Italian peninsula, with a male: female 
ratio of 5:3 and a mean age of 71.6 ± 13.1 years (10) 
(C4). The region of Campania, also in southern Italy, 
was shown to be an area with a high prevalence of Pa­
get’s disease (11) (C4).
PDB rarely appears before the age of 40, but its 
prevalence tends to double every decade starting at the 
age of 50, rising to approximately 10% after ninth de­
cade (12).
Seitz and cols. retrospectively evaluated the bone 
biopsies and medical records of 754 patients historically 
proven to have PDB and found the peak incidence to 
occur between the ages of 70 and 80 years (13) (B3b).
A study from Spain evaluated 4,528 radiographs, in­
cluding all those of the lumbar vertebrae, pelvis, sacrum 
and femoral head in 13 centers studied, reporting a 1% 
incidence of PDB (95% CI: 0.7 to 1.3) in subjects over 
55 years age and an estimated prevalence ranging from 
1.1% (95% CI: 0.8 to 1.4) to 1.6% (95% CI: 1.1 to 2.1), 
with pelvic involvement reported in 60­90% of patients 
considered to have PDB. The prevalence was slightly 
higher in men than in women and significantly greater 
Table 1. Grades of recommendation and strength scientific evidence
A 1 A Systematic review of randomized controlled trials
Systematic reviews of prospective cohort studies
1 B Individual RCT with narrow confidence interval
Prospective cohort studies
B 2 A Systematic review of retrospective cohort studies
2 B RCT with > 20% dropout
Retrospective cohort studies
3 A Systematic review of case-control studies
3 B Individual case-control studies
C 4 Case series
D 5 Expert opinion
RCT: randomized controlled trials.
Diagnosis and management of Paget’s disease of bone
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in individuals over 75 years of age. A considerable geo­
graphical variation in the prevalence was observed (p = 
0.004) in Spain, with 73% of the patients unaware of their 
disease when the radiographs were taken (14) (B3b).
One study, from the US, found a diagnosis of PDB 
in 236 residents of Olmsted County, Minnesota, with 
a mean age of 69.9 years at diagnosis, 55% of those af­
fected being men (15) (C4).
Paget’s disease of bone is extremely rare in Asia 
(16), especially in Korea (17), and among ethnic Chi­
nese (18) (C4). It is also very rare in Japan. A review 
of the literature was carried out of all cases reported 
in Japan from January 1990 to December 2002. Most 
cases (72.1%) were reported by the Department of Or­
thopedic Surgery and a prevalence of 2.8 cases per mil­
lion capita was detected, confirming the rareness of the 
disease in Japanese (19) (B3b).
There is little information available on the existence 
of the PDB in the Arab world. A recent study reported 
four cases of Arab patients with PDB, with variable pre­
sentations, characterizing the existence of the disease in 
the country studied (20) (C4).
A number of studies have reported an unexplained 
downward trend in the prevalence of PDB, some postu­
lating that the disease will become increasingly rare in the 
future (21,22) (B3b). A review of approximately 2,000 
pelvic radiographs, estimated the prevalence of the disease 
in individuals of European descent, over 55 years of age, 
in two New Zealand cities (Dunedin and Auckland). The 
prevalence rate increased with age (p = 0.022), being hi­
gher in men (p = 0.014), but showing no significant gen­
der difference in either of the two cities. The Dunedin data 
was compared to that of another study in the year 1983 in 
the same city, with the prevalence now being roughly half 
the previous level (p = 0.012). In Auckland, the prevalence 
of an isolated raised plasma alkaline phosphatase level (> 
150 U/L, normal range < 120 U/L) was estimated in 
over 80,000 blood samples processed at a community lab­
oratory. The prevalence of “biochemical Paget’s disease”, 
as measured, was very similar to that seen in a radiographic 
study of the same city involving subjects under 80 years of 
age, but not for dose over 80 (23) (B3b).
There are also reports, as in an Australian study, of 
a decrease in incidence and severity of the disease in 
newly diagnosed cases, but for unknown reasons (24), 
with more cases of monostotic disease, whose incidence 
has doubled in the last 30 years. Some reports suggest 
that these findings are more evident in women, as in a 
study conducted in England (25) (B3b).
The prevalence of PDB in Italy was assessed based 
on radiography, scintigraphy, and biochemical data 
from two Italian cities, Siena (central Italy) and Turin 
(northern Italy). At the end of the radiological survey, 
16 of 1,778 cases of pelvic PDB (8 men and 8 women) 
were observed in Siena, and 41 of 6,609 cases (27 men 
and 14 women) in Turin. Disease prevalence was 0.89% 
in Siena, and 0.62% in Turin. Since pelvic involvement 
is normally described in 60 to 90% of the patients with 
PDB, the overall estimated prevalence ranged from 1.0 
to 1.5% in Siena, and 0.7 to 1% in Turin. No decrease 
in the prevalence of PDB was evident after comparison 
of prevalence rates during different time periods. Bio­
chemical analyses showed that 296 of 7,449 subjects 
had elevated levels of alkaline phosphatase and normal 
liver enzymes, 87 of whom had a confirmed diagno­
sis of PDB. The estimated biochemical prevalence was 
1.5%. The scintigraphy study showed an estimated 
prevalence of PDB in 194 of 7,906 cases (2.4%), which 
was significantly higher than radiological and bioche­
mical estimates. This study suggests that PDB in Italy 
has an estimated prevalence of at least 1%, comparable 
to what has been observed in the United States, and 
some European countries, but lower than that reported 
in Great Britain and New Zealand. No secular trend 
indicating decreased prevalence of PDB was observed 
in this study (26) (B3b).
Figure 1 illustrates the extensive geographical varia­
tion in prevalence of PDB worldwide.
Figure 1. Worldwide prevalence studies of Paget’s disease of bone. 
Prevalence studies.
Case series: 145.
Data from references 3,14,21,24,26-33.
EPIDEMIOLOGY OF PDB IN BRAZIL
Epidemiological data on Paget’s disease of bone in Brazil 
are scarce. There are case reports from Rio de Janeiro, 
published in 2000, of PDB involving the maxilla (34) 
Diagnosis and management of Paget’s disease of bone
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(C4) and in 2002 a case series from Recife retrospectively 
analyzed the characteristics of 89 cases (35) (C4). 
The colonization of Pernambuco was strongly influ­
enced by immigrants from Portugal and Holland, many 
of whom were Jews. In Recife, the occupation by the 
Dutch and Jews continued after the initial colonization 
by the Portuguese for political and administrative rea­
sons, which may explain the high frequency of PDB in 
the state of Pernambuco (8,36) (C4).
Bandeira and cols. reported an analysis of 108 cases 
diagnosed in two centers in Recife between 1984 and 
2005 and found that about 90% of the patients were 
of European ancestry. The mean age at diagnosis was 
66.2 years; 49.1% were men; the polyostotic form of the 
disease was the most common; light­colored eyes were 
observed in 22.2% of the patients (data on Brazilian 
general population is not available); 23.1% of the pa­
tients were shown to have a family history of PDB. The 
most affected skeletal locations in this study were the 
pelvis, lumbar vertebrae, femur and cranium. It was also 
found that zoledronate was the most effective drug in 
reducing alkaline phosphatase in these patients (8) (C4).
A Brazilian study about the epidemiology of PDB 
in Brazil evaluated patients aged 45 years or older at­
tending the Osteoporosis Center of the Department of 
Endocrinology and Diabetes of Pernambuco between 
January of 2006, and December of 2009. The age­re­
lated period of prevalence and incidence density were 
both calculated, separately for men and women for each 
year. A total of 7,752 patients were evaluated, 53 of 
whom had PDB. The mean age of patients was 69.53 ± 
8.51 years. The overall prevalence of PDB was 6.8 per 
1,000 patients (p = 0.013, 95% CI 5.1 to 8.9), and the 
incidence density of PDB was 50.3 per 10,000 person­
years (p = 0.026 95% CI 35.8 to 68.8). The prevalence 
and incidence both increased in both sexes during this 
period. These data shows that both the prevalence and 
incidence of PDB in Recife are comparable to the cor­
responding rates in southern Europe (3) (B3b).
A case series from the city of Florianopolis, retro­
spectively evaluated data from patients enrolled in 6 
centers between 1995 and 2009. A total of 134 pa­
tients with PDB were identified, with a mean age at 
diagnosis of 63.2 + / ­10.5 years, of whom 67.2% were 
women and 91.1% white. A positive family history was 
observed in only 8.2% of patients. Polyostotic disease 
was found in 75.0%, bone pain in 77.9%, and bone 
deformities in 15.9%. Higher levels of alkaline phos­
phatase showed a significant association with both the 
Diagnosis and management of Paget’s disease of bone
Figure 2. Sites of bone involvement in 108 cases of polyostotic Paget's 
disease of bone (PDB).
Data from reference 8.
polyostotic form of the disease and involvement of the 
cranium. The pelvic bones were the most frequently 
affected (53.7%). Treatment with zoledronic acid pro­
duced the best results, with only 2.9% of the patients 
failing to show anadequate response (37) (C4).
ETIOLOGY 
The etiology of the disease remains controversial, with 
evidence that genetic along with environmental factors 
are involved. SQSTM1 (sequestosome 1 encoder) is the 
most important gene that has been associated with the 
disease up to now (38) (B3b).
Various loci of susceptibility have been linked to the 
disease, including SQSTM1 and TNFRSF11A (encoder 
of the RANK) on chromosome 18q21­22.SQSTM1, 
also known as p­62 or sequestosome 1, located on 
chromosome 5q35, which is a signaling protein that 
appears to be involved in the pathogenic mechanisms 
that increase the activity of osteoclasts. Random muta­
tions (P392L) of this gene were detected in over 30% 
of PDB family members. The role of SQSTM1/p62 has 
yet to be fully elucidated. There is evidence that mu­
tations may reduce the ability to sequester cytoplasm 
proteins, altering nuclear factor kB (NF­kB), resulting 
in increased osteoclastogenesis (4). The action of os­
teoprotegerine (OPG) on the RANK receptor has also 
been described. The inhibitory effect of the OPG in 
the RANK/RANKL system suggests that mutations 
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causing function loss in the TNFRSF11B gene, encod­
ing the OPG, could also lead to an activating effect in 
the signalization of NF­kB (39) (C4) and there are also 
evidence that TNFRSF11A gene allelic variants interact 
with SQSTM1 mutations to cause the severity of the 
disorder (40) (B3b).
Not only genetic causes have been proposed as the 
etiology of PDB, biological hybridization studies (in 
situ), along with immunohistochemistry, have also 
suggested the possibility of infection of the osteoclasts 
by a virus, mainly paramyxovirus, as being the cause 
of PDB (4) and a study published in 2010 suggested 
that measles virus nucleocapsid gene expression and the 
SQSTM1 mutation both contribute to the increased os­
teoclast activity in PDB (41) (B3b) (42) (C4).
A French study found that half of PDB familial forms 
carried a SQSTM1 mutation (43) (B3b). Other loci that 
predispose to PDB were recently identified by genomic 
association studies that have identified variants at seven 
loci predisposing to the disease. These alone increase 
the risk of PDB from 1.3 to 1.7 times, but they have 
combined effects that affect about 86% of the PDB at­
risk population with negative SQST1 (42) (C4).
Recent studies also suggest that pro­inflammatory 
cytokines are involved in the pathophysiology of Paget’s 
disease of bone. A recent control case study evaluated 
the genomic DNA for functionally active polymor­
phism of the genes of pro­inflammatory cytokines 
(interleukin­1α, interleukin­1 β, interleukin 6), and tu­
mor necrosis factor α, involving 144 PDB patients and 
115 healthy controls. The frequency of genotypes and 
alleles of the polymorphisms examined demonstrated 
practically identical results in both cases and controls. 
Regarding pro­inflammatory genes, patients with PDB 
genotype C/C gene of interleukin 6 (IL­6) showed 
significantly (p < 0.001) greater hearing loss and pri­
mary hyperparathyroidism. There were no significant 
differences in the other clinical features. This study 
does not support the hypothesis that the pro­inflam­
matory genes examined represent an important genetic 
risk factor for PDB. However, data suggests a role for 
the IL­6 gene in modifying the clinical characteristics of 
the disease (44) (B3b).
A study from New Zealand evaluated the rela­
tionship between family history, phenotype, and the 
state of SQSTM1 mutation in patients with a family 
history, and/or severe phenotype of PDB. The sever­
ity of the phenotype was significantly associated with 
the SQSTM1 mutation status, but not with family his­
tory (p < 0.005). SQSTM1 mutations were found in 
10.5% of the patients with early onset, and/or severe 
disease, but without a family history of the disorder 
(38) (B3b).
An earlier study of genomic association had al­
ready identified variants in loci CSF1, OPTN and 
TNFRSF11A, as risk factors for Paget’s disease of bone, 
and an extension of this study identified three new loci 
and recently confirmed these associations with PDB 
in 2,215 affected individuals (cases), and 4,370 con­
trols from seven independent population groups. The 
new associations were with rs5742915 within PML 
on 15q24, rs10498635 within RIN3 on 14q32 and 
rs4294134 within NUP205 in 7q33 and also confirms 
the association of TM7SF4 with PDB. These seven loci 
account for the familial risk for PDB in approximately 
13% of cases (45) (B3b).
There are studies investigating the relationship 
between genetic polymorphisms and sporadic PDB, 
with the aim of identifying polymorphisms represent­
ing susceptibility to the disease. A recent study in­
vestigated the association between polymorphisms in 
three candidate genes and the functional development 
of PDB, TNFSF11 (activator receptor of the nuclear 
factor Kb ligand, RANKL), VCP (valosina­containing 
protein), and IL­6 (interleukin­6), in 196 patients 
with sporadic PDB, and 212 Belgian control subjects, 
and revealed that VCP SNP (rs565070) was associated 
with PDB in this population study (p = 0.5). Through 
the use of genetic testing in the study, no association 
linking TNFSF11 or IL­6 with PDB was confirmed. 
More data are therefore needed because when the 
VCP data is combined with data from other regions, 
involving susceptible genes in previous studies (i.e. the 
TNFRS11A, CSF1, OPTN and TM7SF4 genes), the 
independent effect of each gene region was confirmed 
and the accumulated population attributable risk was 
72.7% (46) (B3b).
Recent studies of genomic association (GWAS) 
confirm the role of the RANK gene in PDB, and also 
indicate the involvement of chromosomal regions that 
harbor the CSF1 and OPTN genes with PDB. A study 
in the Belgian and Dutch populations that attempted 
to replicate these findings also found an association 
between these genes and PDB, being most significant 
in the region of CSF1, followed by the OPTN and 
TNFRSF11A genes. A significant association was also 
discovered with a polymorphism in the chromosomal 
region of the TM7SF4 gene that encodes the DC­
Diagnosis and management of Paget’s disease of bone
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STAMP, which had no significance in association with 
the genomic GWAS, but because of its effect on osteo­
clasts, can be considered a strong candidate gene. The 
cumulative risk attributable to these four loci calculated 
for the two populations studied was shown to be ap­
proximately 67%, indicating that the major part of the 
genetic risk for PDB comes from genetic variants close 
to these four genes (47) (B2b).
Patients with PDB without mutation of the 
SQSTM1 gene seem to be susceptible to genetic poly­
morphisms in regions of the genes CaSR, ESR1, 
TNFRSF11B (OPG), TNFRSF11A (RANK), CSF1 
(M-CSF), OPTN, TM7SF4 (DC-STAMP) VCP, 
NUP205, RIN3, PML, and GOLGA6A, resulting in an 
increased risk for developing PDB. The nature of these 
genes suggests that the regulation of osteoclastogenesis 
has a key role in the pathogenesis of PDB. Moreover, 
the involvement of SQSTM1 and VCP in autophagy 
and the formation of protein aggregates suggest that 
the disruption of these processes may represent a risk 
factor (48,49).
There are also reports of a high prevalence of vita­
min D deficiency in patients with PDB. One possibly 
reason for this is that osteoclast precursors have a high 
responsiveness and sensitivity to 1.25 (OH) 2D3, re­
sulting in increased expression of co­activators of vita­
min D receptors (VDR) in PDB (50) (C4).
In recent years there has been significant progress 
in the study of the epidemiology of PDB. However, 
we still lack a combined evaluation of genetic and envi­
ronmental factors to enable us to fully understand their 
interaction with the etiology of the disease (D5).
CLINICAL MANIFESTATIONS 
Most patients with Paget’s disease of bone (PDB) are 
asymptomatic (51), having been incidentally diagnosed 
through findings from imaging or because of high se­
rum levels of alkaline phosphatase (52) (C4).
The clinical spectrum of PDB is highly variable and 
depends on the sites affected, the type and magnitude 
of the complications, and the metabolic activity (53). 
Although the disease may affect any part of the skeletal 
structure, the pelvis, spine, cranium and long bones are 
the most often affected (15,54) (C4).
Bone pain is the most common symptom. In two 
recently published studies pain was found to be pres­
ent in 40­45% of the patients. It is usually deep, pre­
cisely located and persists when the patient is at rest, 
constant, exacerbated both at night and by weight 
overload. It may occur suddenly as a result of pagetic 
injury, or more frequently, from complications caused 
by the breakdown of bone structure, leading to condi­
tions such as degenerative arthritis, nerve compression 
or sarcomatous degeneration (a rare occurrence present 
in only 1% of cases) (15,55) (C4).
Bone deformities are the second most common mani­
festation with a prevalence ranging from 12 to 36%. They 
occur most commonly in the femur and tibia, causing 
bending, which is characteristically anterolateral in the fe­
mur and anterior in the tibia. These deformities can lead 
to changes in gait and mechanical stress, increasing the 
likelihood of joint degeneration. Involvement of the cra­
nium begins with circumscribed osteoporosis, followed 
years later by increases in volume, regions of sclerosis, an 
enlarged diploe and frontal bossing (15,55) (C4).
We suggest evaluation for PDB in all individuals 
over 50 years of age who present an unexplained eleva­
tion of serum alkaline phosphatase, as well as bone pain 
or deformities (C).
LABORATORY AND IMAGING PROCEDURES
PDB is associated with increased bone turnover, indi­
cated by the elevation of biochemical markers for bone 
formation and resorption. This occurs because a high 
correlation between formation and resorption is main­
tained with PDB. The increase in these markers is pro­
portional to the intensity, size, and number of lesions, 
and may be more pronounced in cases involving the 
cranium. Serum alkaline phosphatase, a bone formation 
marker, has been used for the diagnosis and monitoring 
of patients affected by the disease. However, none of 
the biochemical markers of bone remodeling are enti­
rely specific to bone alone. Serum alkaline phosphatase 
has a sensitivity of 78%, and a specificity of almost 100%. 
However it may be normal in up to 20% of patients with 
monostotic disease (4,56,57). In a study by Bandeira 
and cols. serum alkaline phosphatase was shown to be 
elevated in 92% of the cases. The mean increase was sig­
nificantly more pronounced in patients with the polyos­
totic form than in those with monostotic form of the 
disease (5.9 ± 2.8 vs. 2.2 ± 1.9 times the ULN) (58).
Osteocalcin, considered a specific marker for bone 
formation, was of limited value, whether for the diag­
nosis (normal in 40% of cases) of PDB or for the fol­
low­up. Among the new markers of bone resorption, 
NTX and CTX­β have been shown to have the great­
Diagnosis and management of Paget’s disease of bone
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est diagnostic accuracy (59). Recent data has demon­
strated a significant reduction in CTX after use of oral 
ibandronate. After six months of treatment, the mean 
decrease in CTX was 65.24 ± 9.28%, with reductions 
greater than 80% in seven of the patients. One patient 
with normal sCTX showed a reduction of 97.5% by the 
end of the treatment (60) (B2b). As with beta­CTX, 
there was evidence of a greater reduction in the ratio of 
urinary αC­telopeptide of type 1 collagen tocreatinine 
(mg/nmol of creatinine) with the infusion of zoledron­
ic acid, when compared to risedronate (61) (B3b).
Serum calcium and phosphorus levels are normal in 
most patients. Hypercalcemia and hypercalciuria may 
occur in the case of immobilization or fracture. The 
finding of hypercalcemia normally points to a second­
ary disorder such as hyperparathyroidism.
Bone scintigraphy followed by radiography of the 
affected areas determines the extent of involvement of 
the bone in Paget’s disease. Sites of increased uptake 
occur as a result of the high rate of bone formation 
and blood flow. As a more sensitive method, bone scan 
with Tc 99­MDP can be positive even before the lytic 
changes seen on plain radiography. For this reason, 
about 10­15% of lesions detected by scintigraphy ap­
pear normal on plain radiographs. Comparing results 
from both methods, bone scintigraphy and radiography 
show alterations 56 to 86% of the time, with 2­23% of 
the cases showing alterations only in the scintigrams, 
and 11­20% only in the radiographs. The late stages of 
the disease may show a normal uptake of the radiophar­
maceuticals, owing to the declinein metabolic activity 
and alterations in the findings of plain radiography. The 
characteristic findings of plain radiography are hyperos­
tosis, osteosclerosis and bone expansion. CT and MRI 
provide little additional information when dealing with 
uncomplicated cases of the disease. They can be useful 
when complications associated with PDB are suspected, 
such as fractures or sarcomatous degeneration of page­
tic bone. Due to the excellent resolution, MRI is the 
method of choice for the staging of sarcomatous de­
generation (62). It can also be useful in the evaluation 
of neurological complications, such as compression of 
spinal nerve roots and cranial nerves (62­65) (C4).
COMPLICATIONS 
Clinical manifestations of the disease are usually related 
to the presence of complications, which can be classi­
fied according to the particular system involved: ske­
letal (bone pain, osteoarthrosis, fractures, deformities 
and hypercalcemia), cardiovascular (high output heart 
failure, vascular calcifications, and valvular stenosis), 
neurological (deafness, increased intracranial pressure, 
and cranial nerve dysfunction), metabolic (hyperurice­
mia, hypercalciuria, hypercalcemia and nephrolithiasis) 
and neoplastic (osteosarcoma and giant cell tumors) 
(66­68) (D5).
Osteoarthritis is a common complication, most of­
ten affecting the knee and hip joints, resulting in the 
modification of bone biomechanics that causes bone 
and cartilage degeneration. Rheumatoid arthritis and 
its variants, as well as arthropathy from crystal deposi­
tion, have also been associated with the disease (69) 
(D5). Deformities and fractures are the result of ab­
normal bone formation, and associated with high 
morbidity due to the high incidence of associated pain 
(70) (D5). The involvement of cranial bones can cause 
neurological complications such as hearing loss (either 
neurosensorial or conductive), headache, dizziness, and 
more rarely, vascular dementia and hydrocephalus. In­
volvement of the jaw bones may lead to periodontal 
disease and dental malocclusion (66,67) (D5).
Malignant transformation of pagetic bone involv­
ing osteosarcoma or giant cell tumor is rare, occurring 
in less than 1% of cases. It classically affects individuals 
with the polyostotic form of the disease, and manifests 
itself accompanied by an increase in bone pain, swell­
ing, and more rarely, pathologic fracture (71­74) (D5).
Hypercalcemia is often associated with prolonged 
immobilization or dehydration. Cardiovascular chan­
ges, although described, are rarely evident in clinical 
practice (75) (D5). Because PDB is a chronic disease, 
and diagnosed belatedly, it is important to be aware of 
the signs and symptoms that indicate the need for fur­
ther radiological investigation.
TREATMENT
Pharmacological treatment seeks to promote pain relief 
and reduce the rate of bone remodeling. Restoration 
of typical bone turnover normalizes the rate of bone 
deposition, reducing bone vascularization, and slowing 
progression of the disease.
Symptomatic patients (with secondary symptoms 
of metabolically active disease) should be treated. The 
most common symptom is bone pain at a pagetic site. 
The exact cause of pain in these patients may be diffi­
cult to determine, and the initiation of drug therapy in 
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these cases is usually indicated by a concomitant eleva­
tion of serum alkaline phosphatase (76­78) (D5).
The asymptomatic form of the disease is often de­
tected by imaging studies, motivated by suspicion of 
other diseases, or by observation of persistently elevat­
ed levels of serum alkaline phosphatase. Therapeutic 
decisions involving affected patients should take into 
account the location of the disease in sites that are 
susceptible to complications, such as the cranium and 
spine, in addition to abnormally high alkaline phos­
phatase levels (two to four times above the upper limit 
considered normal), and the presence of co­morbidi­
ties (79).
Other indications for treatment of asymptomatic 
patients include planned surgery at an active pagetic 
site in order to reduce the risk of bleeding (including 
blood loss during surgery), along with the rare possi­
bility of developing hypercalcemia associated with the 
immobilization of patients with the polyostotic form of 
the disease (76) (D5).
We suggest the initiation of pharmacological treat­
ment for all symptomatic patients, for preoperative as­
ymptomatic patients requiring bone surgery, those with 
hypercalcemia, and cases involving locations liable to 
present complications (C).
PHARMACOLOGICAL TREATMENT MODALITIES
Several treatment modalities have been employed in an 
effort to care for patients with Paget’s disease. They 
involve agents that target osteoclasts, the primary cells 
responsible for the disease, and that act by suppressing 
bone resorption within days or weeks. Most researchers 
conclude that these drugs are best considered as tools 
for helping to control the disease, rather than being a 
definitive therapy (80) (A1b).
The first therapy used for Paget’s disease (in the 1970s) 
involved salmon calcitonin, followed later by human cal­
citonin. The medication acts directly on calcitonin recep­
tors located on the osteoclasts. Owing to its short dura­
tion of action, partial response, and acquired resistance, it 
is used only in those with intolerance to bisphosphonates 
(81) (D5). Although radiological improvement has been 
reported during treatment, recurrence is common after 
the medication is discontinued. Side effects are common, 
including flushing, nausea and vomiting (22) (D5).
The efficacy of parenteral salmon calcitonin was 
evaluated in a trial involving 85 patients. Alkaline phos­
phatase levels and urinary hydroxyproline excretion de­
creased by approximately 50% after the first few months 
of therapy. However, in 22 of the 85 patients, despite 
the continued treatment, these parameters returned to 
pretreatment levels. Nineteen patients were considered 
treatment­resistant, presenting elevated amounts of an­
tibodies to calcitonin (82) (B2b). The usual initial dose 
is 50 to 100 units per day (as tolerated), and the main­
tenance dose is normally 50 units daily, or 50 to 100 
units every three days. The intranasal formulation, easy 
to administer, can be as effective as parenteral therapy, 
but has not yet been approved in the United States for 
this specific purpose (83,84) (D5).
Currently, the most widely used agents for treating 
the disease are the bisphosphonates, a broad class of 
medications that work by blocking osteoclastic bone 
resorption. Nitrogenous bisphosphonates (alendro­
nate, risedronate, pamidronate, and zoledronic acid) 
are the drugs of choice (60,79) (A1b).
The first bisphosphonate used for the treatment of 
Paget’s disease (in 1971) was the etidronate form, a 
non­nitrogenous bisphosphonate. The recommended 
dosage is 5 mg/kg per day (mean dose 400 mg/day) 
for six months. In general, patients with very active 
forms of the disease experience moderate clinical and 
biochemical improvement, followed by rapid relapse 
after stopping the medication. In addition, there is a 
tendency to become resistant to the medication after 
repeated courses of therapy (85) (D5).
Clodronate has greater potency than etidronate, 
and does not lead to mineralization defects. It should 
be administered intravenously at dose levels of 300 mg 
daily for 5 days. However, it is generally less effective 
than pamidronate (86) (B2b).
In the non­nitrogenous class of bisphosphonates, 
tiludronate is recommended in doses of 400 mg/day for 
3 months, normalizing alkaline phosphatase in 35% of pa­
tients. It is more effective than etidronate, and does not 
cause bone demineralization. In a randomized, placebo­
controlled trial, 149 patients used tiludronate at doses of 
400 and 800 mg/day for three months, presenting a sig­
nificant reduction in bone markers and pain (87) (A1b).
Alendronate is used at dose levels of 40 mg daily 
for six months. It is generally a well­tolerated drug, ef­
fective in normalizing serum alkaline phosphatase. It 
should not be used in patients with creatinine clearance 
below 35 ml/min (88) (A1b).
In a study involving 89 patients with active disease, 
a group treated with 40 mg of alendronate daily for six 
months showed a significantly greater reduction in alka­
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line phosphatase (79% vs. 44%), and urinary deoxypyrid­
inoline (75% vs. 51%) than a group treated with 400 mg 
of etidronate (p < 0.001 in both cases). Alendronate was 
well tolerated, and had a safety profile similar to that of 
etidronate (89) (A1b). In an open trial lasting two years, 
72 patients with Paget’s disease were assigned to receive 
either 60 mg of pamidronate every 3 months or 40 mg 
of alendronate daily for 3 months. The study concluded 
that alendronate and pamidronate have similar efficacy 
in achieving biochemical remission (90) (A1b).
Risedronate is used in 30­mg doses daily for two 
months, but should not be administered to patients 
with a creatinine clearance of less than 30 ml/min. In an 
American multicenter study, 62 patients received risedro­
nate, 30 mg daily for 2 months, and 61 patients received 
etidronate, 400 mg daily for 6 months. Serum levels of 
alkaline phosphatase were controlled in 73% of the pa­
tients treated with risedronate, compared with 15% of the 
patients who received etidronate (P < 0.001). The aver­
age time for normalization was 91 days for the patients 
treated with risedronate, and 360 days for the patients 
treated with etidronate (P < 0.001). Relapse rates were 
3% in the risedronate group and 15% in the etidronate 
group (P < 0.05). Pain reduction was statistically signifi­
cant in the risedronate group, but not in the etidronate 
group. Both drugs were well tolerated (91) (A1b).
Pamidronate is well tolerated and can be used with a 
clearance above 30 ml/min. It is administered intrave­
nously in 30 mg doses daily for three days. One drawback 
to its use is the development of resistance, which may 
influence the effectiveness of retreatment (92) (A1b). It 
may lead to a fall in serum alkaline phosphatase by 70% 
and about 60­80% will normalize it. The response is bet­
ter in patients with higher values at baseline (93). 
Ibandronate has been used safely and effectively in 
treating Paget’s disease with 2 mg intravenous doses 
(94) (B2b). Recent data from a series of cases shows 
a significant reduction in the levels of sCTX, and in 
the algic aspect following oral use of ibandronate with 
150 mg doses per month for six months. After six 
months of treatment, there was a mean reduction in 
sCTX of 65.24 ± 28.9%, and reduction of more than 
80% in 58.3% of the patients studied. One patient with 
normal sCTX showed a reduction of 97.5% at the end 
of the treatment period. The mean reduction in alka­
line phosphatase was 49.21 ± 37.9%, with all patients 
presenting normal levels after the treatment. There 
was a significant clinical response in all patients, with a 
marked improvement in bone pain (60) (C4).
Zoledronic acid is the most potent bisphosphonate 
approved for use in cases of Paget’s disease. Adminis­
tered in a single intravenous dose of 5 mg, it is not 
recommended for patients with a clearance below 35 
ml/min. Sustained remissions are achieved in most pa­
tients, lasting up to two years (61) (A1b). This finding 
was confirmed when the study was extended for 6.5 
years (95). Zoledronic acid can lead to a more rapid and 
prolonged remission during the treatment of Paget’s 
disease when compared to risedronate. When evaluated 
for six months, using a single 5 mg infusion adminis­
tered over 15 minutes, the effective response being 
considered normalization of alkaline phosphatase (or a 
decrease of at least 75%), it resulted in a 96% reduction 
in alkaline phosphatase, compared with a 74.3% reduc­
tion with risedronate when administered in daily 30 mg 
doses for 3 months. Normalization of alkaline phos­
phatase levels was more frequently achieved in patients 
treated with the zoledronic acid (88.6% vs. 57.9%) than 
in with those receiving risedronate (96) (A1b).
We indicate the use of nitrogenated bisphosphonates 
(alendronate, risedronate, pamidronate, and zoledronic 
acid) for the treatment of Paget’s disease, emphasizing 
that zoledronic acid is the most potent bisphosphonate 
for use with this disease. (C)
MONITORING DISEASE ACTIVITY
Alkaline phosphatase, being a marker for bone remo­
deling, is commonly used as a parameter for measuring 
the biochemical response to treatment with bisphos­
phonates. Normalization of the alkaline phosphatase 
level is associated with biochemical remission, histolo­
gical evidence of normal bone turnover, and its eleva­
ted level is related to the increase in disease activity. The 
measurement of alkaline phosphatase levels should be 
conducted after the first three to six months of treat­
ment, in order to evaluate the initial response, followed 
by two annual measurements as a marker of bone acti­
vity (92) (D5).
Tiludronate, a weak bisphosphonate is available in 
some countries, mainly to treat monostotic disease. In 
a clinical trial involving twenty­one patients with PDB 
receiving 400 mg of tiludronate daily for three months, 
treatment response was observed six months after dis­
continuation of therapy, while the relapse of the disea­
se, when present, was observed one year after the end 
of treatment (97) (B2b).
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In a case series study, significant reductions in the 
levels of alkaline phosphatase and serum CTX were 
demonstrated after six months of treatment with orally 
administered ibandronate at dosages of 150 mg per 
month for six months. After 6 months of treatment, 
the mean reduction in CTX was 65.24 ± 28.9%, de­
ceasing more than 80% in 7 patients. One patient with 
normal CTX showed a reduction of 97.5% at the end 
of the treatment period. The average reduction in alka­
line phosphatase was 49.21 ± 37.9%, with all patients 
presenting normal levels after the treatment, suggesting 
that the follow­up of patients with PDB should also 
include CTX levels (60) (B2b).
Remission is considered to have been achieved 
when normal levels of alkaline phosphatase are attained, 
and partial remission when there is a decrease in levels 
greater than 75% after three to six months of treatment. 
Treatment should be resumed when alkaline phospha­
tase levels begin to rise again (when treatment involves 
normalization), or when there is a 25% increase com­
pared to post­treatment levels (98) (D5).
We suggest the measurement of serum alkaline 
phosphatase after three and six months from the start 
of treatment in order to monitor the initial response, 
followed by biannual measurements of markers indicat­
ing disease activity (B).
NATURAL HISTORY OF PDB
Several clinical guidelines cast doubt on the belief that 
the treatment of Paget’s disease alters the history of 
disease complications. Results from the PRISM study 
showed that most treatment approaches have limited 
impact on quality of life, pain and hearing loss, and hi­
ghlighted the need for further studies to examine whe­
ther the effects of bisphosphonates on bone remodeling 
can actually translate into a clinical improvement and 
lower risk of complications in the individuals affected 
(99) (B2b). On the other hand the follow­up was too 
short to show the expected beneficial effects on chro­
nic complications of the disease. Long­term studies are 
therefore needed in order to assess the impact of treat­
ment on the natural history and progression of PDB.
CONCLUSIONS
Paget’s disease of bone has a variable geographic distri­
bution worldwide, being most commonly encountered 
in white Europeans, and those of European descent over 
55 years of age. In Brazil, a prevalence study in a city 
originally colonized by Europeans identified rates com­
parable to those encountered in southern Europe. The 
etiology of the disease still remains controversial, with 
evidence that genetic factors are involved, particularly 
those relates to SQTM1 and genetic polymorphisms in 
sections of the following genes: CaSR, ESR1, TNFRS-
F11B (OPG), TNFRSF11A (RANK), CSF1 (M-CSF), 
OPTN, TM7SF4 (DC-STAMP), VCP, NUP205, RIN3, 
PML and GOLGA6A (1,4). Environmental factors, 
along with viral and proinflammatory cytokines may 
also be involved. The clinical presentation is quite ex­
tensive, with bone pain, fractures, skeletal deformities 
and secondary arthrosis comprising part of the pictu­
re. The diagnosis is made primarily by characteristic 
radiological findings and high alkaline phosphatase. 
The most common complications include pathologic 
fractures, bone deformities and osteoarthrosis. Malig­
nant transformation of pagetic bone is rare. Treatment 
should be recommended for all symptomatic or asymp­
tomatic patients, during the preoperative phase of bone 
surgery, or when hypercalcemia or support bones are 
involved. Nitrogen contained bisphosphonates are the 
medications of choice, with zoledronic acid being the 
most potent bisphosphonate approved for pharmaco­
logical treatment. Newer compounds such as deno­
sumab, a monoclonal antibody against RANKL may 
show promises for the treatment of PDB, although data 
are still lacking. Serial measurements of serum alkaline 
phosphatase should be used to monitor disease activity, 
combined with clinical monitoring of the patient.
Disclosure: no potential conflict of interest relevant to this article 
was reported.
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